Mosaic ImmunoEngineering Inc.

Mosaic’s lead candidate MIE‑101 has demonstrated strong preclinical anti-tumor activity by stimulating innate immunity through intra-tumoral administration of cowpea mosaic virus nanoparticles. Data support advancement into human clinical trials for multiple cancer types. The company recently agreed to acquire clinical-stage necroptosis cancer therapy assets from Oncotelic Therapeutics, expanding its pipeline and access to an AI-driven immunotherapy combination discovery platform. Academic collaborators have received significant grant funding supporting the technology’s development in both oncology and infectious disease models. No human trial results reported as of May 2025.[2][5][6]